Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon develops targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases, with programs built around C1q and the classical complement pathway. Company news centers on clinical and regulatory progress for vonaprument in geographic atrophy, tanruprubart in Guillain-Barré syndrome, and ANX1502 as an oral C1 inhibitor for autoimmune disease.
Recurring updates also include quarterly financial results, research and development spending, cash runway disclosures, investor conference presentations, key opinion leader events, and equity inducement grants under Nasdaq rules. The company’s announcements connect pipeline progress with its balance sheet and public-company governance activity.
Annexon appoints Thomas G. Wiggans as Chairman
On February 8, 2021, Annexon (Nasdaq: ANNX) announced the appointment of Thomas G. Wiggans as its new Chairman. This change follows the retirement of William Young and Carol Gallagher from the board. The company also welcomed Dr. William H. Carson to the board, who has extensive experience in CNS disorders from his previous role as president and CEO at Otsuka Pharmaceutical. Both appointments aim to enhance Annexon's strategic direction as it advances its clinical-stage C1q inhibitors.
Annexon, Inc. (Nasdaq: ANNX) presented at the J.P. Morgan 39th Annual Healthcare Conference, highlighting its achievements and 2021 milestones. The company initiated multiple clinical trials in 2020, including Phase 2/3 trials for ANX005 in Guillain-Barre Syndrome and Huntington’s Disease. Annexon secured $262.7 million from an IPO and is focused on complement-mediated disorders. Key 2021 goals include new clinical trials and data releases for its investigational monoclonal antibodies. CEO Douglas Love emphasized a strong capital position and leadership for future growth.
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical firm focused on autoimmune and neurodegenerative disorders, announced a corporate update presentation at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 4:30 PM ET. The event will be accessible via a live webcast on their Investors page, with a replay available for 30 days post-event. Annexon is developing innovative therapies based on its technology targeting classical complement-mediated disorders, employing a biomarker-driven strategy to enhance patient identification and treatment response evaluation.
Annexon, Inc. (Nasdaq: ANNX) has initiated patient dosing in a Phase 2/3 clinical study evaluating ANX005, a monoclonal antibody targeting Guillain-Barré Syndrome (GBS), a severe autoimmune disorder. With no approved treatments currently available in the U.S., ANX005 has been granted Fast Track and Orphan Drug designations. The trial aims to assess ANX005's efficacy in improving patient disability. Previous trials show promising results with significant biomarker reductions. The company continues to explore additional applications for ANX005 in complement-mediated autoimmune diseases.
Annexon reported third quarter 2020 results on November 16, showcasing a cash balance of $370.7 million as of September 30, 2020, bolstered by a successful IPO. The company has initiated a Phase 2 trial for ANX005 in Huntington’s Disease and completed enrollment in a Phase 1b trial for Guillain-Barré Syndrome (GBS). R&D expenses increased to $11.8 million and net loss widened to $15.6 million. The company is well-capitalized to advance several crucial clinical trials targeting complement-mediated diseases.
Annexon has initiated a Phase 2 study for its monoclonal antibody ANX005, targeting Huntington's Disease (HD). The trial aims to dose 24 patients and assess safety, tolerability, and biomarkers related to neurodegeneration. ANX005 works by inhibiting C1q, a protein implicated in synapse loss and neuroinflammation. The company, focused on complement-mediated disorders, anticipates initial trial results in H2 2021. It has previously received fast track and orphan drug designations for ANX005 in Guillain-Barré Syndrome.
Annexon has reported its second quarter 2020 financial results, highlighting a completed $263 million IPO in July and a private financing round in June that raised $96.8 million. The company is set to initiate four new clinical trials by year-end, including trials for ANX005 in expanded indications. As of June 30, 2020, cash and cash equivalents reached $124.8 million, a significant increase from $43.9 million at the end of 2019. However, net loss for the quarter amounted to $12.5 million, higher than the previous year's loss of $9.7 million.
Annexon, Inc. (Nasdaq: ANNX) has appointed Michael Overdorf as Chief Business Officer, effective July 30, 2020. Overdorf brings nearly 20 years of pharmaceutical experience, having spent 19 years at Eli Lilly in various leadership positions, including Corporate Business Development. His expertise will support Annexon's strategic commercial and business development efforts, especially concerning its promising pipeline of therapies targeting classical complement-mediated disorders. CEO Douglas Love expressed confidence in Overdorf's role to enhance corporate growth and patient access to therapeutic alternatives.
Annexon, Inc. (Nasdaq: ANNX) announced the closing of its initial public offering of 14,750,000 shares of common stock at $17.00 per share, generating approximately $250.8 million in gross proceeds. The stock began trading on July 24, 2020, with a 30-day option for underwriters to purchase an additional 2,212,500 shares. J.P. Morgan, BofA Securities, and Cowen are the joint book-running managers. This follows the effective registration of the offering on July 23, 2020. Annexon focuses on therapies for classical complement-mediated disorders, with an emphasis on autoimmune and neurodegenerative diseases.